Natureza’s Novelty of Formulations

  • Mode of Action: Incorporation into cell membrane affecting cell signalling and thus cell division.
  • Safety: Completely safe.
  • Resistance: None
  • Delivery system: Novel
  • No Residues
  • Products with activity against MDR Gram-positive, Gram-negative and fungal pathogens

Natureza’s Solutions

Natureza® outsources the high level expertise necessary to pursue research aimed at addressing the challenge of the current global crisis of Anti Microbial Resistance.

The company aims to adequately reward its employees and investors to ensure the continued stability and growth of the company and its continued development of products that meet important health needs.

Company Information

Natureza® was incorporated in 2009 as a US Texas Private Research and Development company. It presently has 2 anti-infectives in preclinical development. The latest technology has been granted patents worldwide and has multiple patents pending domestically and internationally. Formulations are effective against antibiotic resistant pathogens. Laboratory trials have shown that no resistance has developed in pathogens to these novel agents during long term repeated exposure. This research was an extension of earlier developments from its affiliate company, BioSafe Technologies, Inc. also a US Texas Company incorporated in 2000.

BioSafe Technologies, Inc. developed formulations for pesticide use from natural compounds discovered in South America. The company obtained 24 US and international patents and multiple trademarks and has been manufacturing and exporting a proprietary brand of head lice treatments in the US and via several multinational pharmaceutical companies for over a decade averaging over 5 million bottles of product sold. Business expanded in the US via pharmacy chain stores and internet with Amazon and Walmart.com.

A non toxic insect repellent is in final stages of development. Laboratory in vitro bioassays showed the BioSafe repellent formulation provided 100% repellency for over 6 hours to Aedes aegypti and Culex quinquefasciatus over a 6-hr period exceeding protection provided by a product sample containing 15% DEET.

BioSafe sold multiple patents to Natureza®, Inc. at the time of Natureza’s incorporation and contributed a significant investment in the company for further development and testing of its active ingredient formulations to control endoparasites in humans and animals. The BioSafe management team was contracted by Natureza® to assist in the administration procedures and the research activities having Dr. Gerald Coles as a Scientific Advisor. Results from this research in the UK and South America showed activity against endoparasites in addition to the enhancing of the healing of skin wounds, burns and having bacteriostatic properties against gram positive bacteria.

All are effective against antibiotic resistant Gram-negative and positive pathogens in the WHO priority list, with three agents active against Priority 1 critical pathogens. The group of agents together show proven in vitro activity against 12 of the 15 antibiotic resistant bacteria listed by the WHO as causing the highest levels of concern. Laboratory trials have shown that no resistance has developed in pathogens to these novel agents during long term repeated exposure, and that no intrinsic resistance can be detected in target pathogens. The agents have a strong safety profile, with GRAS status in the USA.

About BioSafe Technologies, Inc.

BioSafe Technologies, Inc was incorporated in 2000 to further develop, clinically test and create a distribution of nontoxic pesticide formulations for eliminating parasites and other blood sucking insects such as mites and lice affecting humans and animals. The active ingredients were discovered by its founder, Lynn James-Meyer during field testing in Brazil in the early 1990s. The formulations were brought to the US and obtained worldwide patents and further tested for safety and efficiency. All function as cleansers and do not contain poisonous insecticides.

Since 2003 BioSafe based the majority of its business as an exporter supplying overseas distributors. It contracted with several filling facilities in the Dallas, Texas area for bulk packaging of its headlice shampoo in 1000 liter totes. These are exported to various locations in Europe for further private labeling and distribution by several large pharmaceutical companies. Product is sold in Europe and other countries in children’s specialized lines of products.

BioSafe has successfully worked with the US EXIM Bank Export Program to support the growth of the company since 2009. A testament to the success of that partnership was Lynn’s selection as Global Exporter of the Year in 2016 by the Dallas Branch of the Global Chamber where she serves on the Board Advisory Committee. As a woman owned company, she also received various awards for Women in Business in 2017.

Discover The Future

Discover Natureza® Products.

Contact Us